{"entity":{"id":"nct05192798","kind":"trial","name":"Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC","aka":[],"tldr":"A phase 2 trial of nab-paclitaxel, rivoceranib (apatinib) and bevacizumab in triple-negative breast cancer, run by The First Affiliated Hospital of Bengbu Medical University, now recruiting.","summary":"Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC is a phase 2, randomised interventional study registered as NCT05192798 by The First Affiliated Hospital of Bengbu Medical University, with a registry enrolment figure of 128 participants, started 2022-01-14 and due to reach its primary completion in 2027-09-10. Interventions recorded: Albumin-Bound Paclitaxel; Apatinib Mesylate; Bevacizumab. Conditions listed: Triple-negative Breast Cancer. Triple-negative eligibility wording from the registry: \"Patients with recurrent or metastatic triple negative breast cancer confirmed by histopathology and imaging;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05192798","url":"https://clinicaltrials.gov/study/NCT05192798"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["nab-paclitaxel","rivoceranib","bevacizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05192798","phase":"2","setting":"A Prospective, Randomized, Open Label Clinical Study Evaluating Efficacy and Safety of Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic Triple Negative Breast Cancer","sponsor":"The First Affiliated Hospital of Bengbu Medical University","enrolled":128,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05192798/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"nab-paclitaxel","kind":"drug","name":"Nab-paclitaxel","route":"/drugs/nab-paclitaxel/"},{"id":"rivoceranib","kind":"drug","name":"Rivoceranib (apatinib)","route":"/drugs/rivoceranib/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}